ASCO 2019 | PEACE III: radium-223 vs. enzalutamide for mCRPC

Bertrand Tombal • 1 Jun 2019

Genitourinary Cancer Prostate Cancer Abiraterone Enzalutamide Radium-223

Bertrand Tombal, MD, PhD, of the Cliniques Universitaires Saint-Luc, Brussels, Belgium, discusses the results of the PEACE III (NCT02194842) trial investigating Radium-223 vs. enzalutamide for metastatic bone dominant castration-resistant prostate cancer (mCRPC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

ARASENS: dialuramide plus ADT and docetaxel for metastatic hormone-sensitive prostate cancer

Bertrand Tombal • 17 Mar 2023

HERO: relugolix as an oral androgen-deprivation therapy in prostate cancer

Bertrand Tombal • 4 Jul 2022

ARASENS: dialuramide plus ADT and docetaxel in mHSPC stratified by disease risk + volume

Bertrand Tombal • 17 Mar 2023

Considerations for the long-term effects of androgen deprivation therapy

Bertrand Tombal • 16 Nov 2018

Related Videos

Cabozantinib plus docetaxel and prednisone in mCRPC

Munjid Al Harthy • 18 Feb 2019

Challenges of nmCRPC management: to treat or not?

Robert Jones • 18 Jan 2019

How to involve patients in clinical decision making

Joe O'Sullivan • 29 Nov 2018

Improving the current chemotherapy standard: a role for DNA methyltransferase inhibitors

Simon Crabb • 16 Nov 2018